Journal
NATURE CLINICAL PRACTICE RHEUMATOLOGY
Volume 4, Issue 6, Pages 300-309Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncprheum0797
Keywords
AdAM; clinical trial; rheumatoid arthritis; TACE; TNF
Categories
Ask authors/readers for more resources
The success of agents that inhibit tumor necrosis factor (TNF), such as infliximab, adalimumab and etanercept, has led to a desire for orally available small molecules that have a better safety profile and are less costly to produce than current agents. One target for anti-TNF therapy that is currently under investigation is TNF-converting enzyme, which promotes the release of soluble TNF from its membrane-bound precursor. Inhibitors of this enzyme with drug-like properties have been made and tested in the clinic. These inhibitors include TMI-005 and BMS-561392, both of which have entered into phase II clinical trials. This article summarizes preclinical and clinical findings regarding the use of inhibitors of TNF-converting enzyme for the treatment of rheumatoid arthritis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available